Justice Department Briefing 2025-07-25
Estimated reading time: 5 minutes
1. Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection; Requirement That Movie Theaters Provide Notice as to the Availability of Closed Movie Captioning and Audio Description for Digital Movies
Sub: Justice Department
Content: The Civil Rights Division, Disability Rights Section (DRS) Department of Justice will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
2. Taha Dias, M.D.; Decision and Order
Sub: Justice Department, Drug Enforcement Administration
3. Notice Pursuant to the National Cooperative Research and Production Act of 1993-America’s Datahub Consortium
Sub: Justice Department, Antitrust Division
4. Notice Pursuant to the National Cooperative Research and Production Act of 1993-Decentralized Storage Alliance Association
Sub: Justice Department, Antitrust Division
5. Notice Pursuant to the National Cooperative Research and Production Act of 1993-1EdTech Consortium, Inc.
Sub: Justice Department, Antitrust Division
6. Notice Pursuant to the National Cooperative Research and Production Act of 1993-Bytecode Alliance Foundation
Sub: Justice Department, Antitrust Division
7. Agency Information Collection Activities; Proposed eCollection eComments Requested; New collection; Title-User Access Request Form for EPIC System Portal (ESP)
Sub: Justice Department
Content: The Drug Enforcement Administration, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
8. Schedules of Controlled Substances: Extension of Temporary Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
Sub: Justice Department, Drug Enforcement Administration
Content: The Acting Administrator of the Drug Enforcement Administration (DEA) is issuing this temporary scheduling order to extend the temporary schedule I status of five designer benzodiazepines–clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam. In an order dated July 26, 2023, DEA temporarily placed these five substances in schedule I of the Controlled Substances Act. This temporary order will extend the temporary scheduling of five designer benzodiazepines for one year, or until the permanent scheduling action for these substances is completed, whichever occurs first. As a result of this order, the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances will continue to be imposed on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these five specified controlled substances.
9. Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
Sub: Justice Department, Drug Enforcement Administration
Content: The Drug Enforcement Administration proposes placing clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam and their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, as identified in this proposed rule, in schedule I of the Controlled Substances Act. These five substances were temporarily scheduled in an order dated July 26, 2023, and subsequently extended until July 26, 2026, pursuant to an extension published elsewhere in this issue of the Federal Register. This action will also enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle these five specific controlled substances.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
